ATE496630T1 - Immunologische zusammensetzung und impfstoffe, die einen auf n-formyl-methionyl peptide bestehenden adjuvans enthalten - Google Patents

Immunologische zusammensetzung und impfstoffe, die einen auf n-formyl-methionyl peptide bestehenden adjuvans enthalten

Info

Publication number
ATE496630T1
ATE496630T1 AT07007842T AT07007842T ATE496630T1 AT E496630 T1 ATE496630 T1 AT E496630T1 AT 07007842 T AT07007842 T AT 07007842T AT 07007842 T AT07007842 T AT 07007842T AT E496630 T1 ATE496630 T1 AT E496630T1
Authority
AT
Austria
Prior art keywords
formyl
vaccines containing
immunological composition
adjuvant consisting
methionyl peptides
Prior art date
Application number
AT07007842T
Other languages
English (en)
Inventor
Jeannine Alexander
William I Cox
Original Assignee
Connaught Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Technology Corp filed Critical Connaught Technology Corp
Application granted granted Critical
Publication of ATE496630T1 publication Critical patent/ATE496630T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92—Detection of biochemical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT07007842T 1998-12-18 1999-12-17 Immunologische zusammensetzung und impfstoffe, die einen auf n-formyl-methionyl peptide bestehenden adjuvans enthalten ATE496630T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/216,702 US6017537A (en) 1998-12-18 1998-12-18 Formyl methionyl peptide vaccine adjuvant

Publications (1)

Publication Number Publication Date
ATE496630T1 true ATE496630T1 (de) 2011-02-15

Family

ID=22808169

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99969285T ATE359817T1 (de) 1998-12-18 1999-12-17 Auf n-formyl methionyl peptide basierendem adjuvans für impfstoffe
AT07007842T ATE496630T1 (de) 1998-12-18 1999-12-17 Immunologische zusammensetzung und impfstoffe, die einen auf n-formyl-methionyl peptide bestehenden adjuvans enthalten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT99969285T ATE359817T1 (de) 1998-12-18 1999-12-17 Auf n-formyl methionyl peptide basierendem adjuvans für impfstoffe

Country Status (14)

Country Link
US (1) US6017537A (de)
EP (2) EP1140166B1 (de)
JP (1) JP2002532436A (de)
AT (2) ATE359817T1 (de)
AU (1) AU773697B2 (de)
CA (2) CA2718376A1 (de)
CY (2) CY1106635T1 (de)
DE (2) DE69935866T2 (de)
DK (2) DK1140166T3 (de)
ES (2) ES2284285T3 (de)
NZ (1) NZ510544A (de)
PT (2) PT1800692E (de)
SI (2) SI1800692T1 (de)
WO (1) WO2000035482A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010018579A1 (en) 1998-12-18 2001-08-30 Walter Klemp Disposable absorbent garment having stretchable side waist regions
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
AU2001264892B2 (en) * 2000-05-23 2006-03-16 Mowycal Lending, Llc Modulaton of alpha-6 integrin-mediated responses
CA2950109C (en) * 2000-10-27 2019-02-19 John W. Hadden Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) * 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
JP2006516883A (ja) 2002-09-19 2006-07-13 アメリカ合衆国 P.アリアシポリペプチド、ユウガイサシチョウバエポリペプチド、および使用法
DE60327366D1 (de) 2002-10-29 2009-06-04 Fundacao Oswaldo Cruz Lutzomyia longipalpis-polypeptide und verwendungsverfahren
US7270949B2 (en) * 2003-01-07 2007-09-18 Neuromed Pharmaceuticals Ltd. Fluorescence based T-type channel assay
US7425700B2 (en) * 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
EP1734991A4 (de) * 2004-04-14 2012-10-24 Avirid Inc Zusammensetzungen mit modifizierten, auf virale nukleinsäuren gerichteten nukleasen und verfahren zur verwendung für prävention und behandlung von viruserkrankungen
US7998733B2 (en) 2004-10-05 2011-08-16 Merial Limited Chimeric vectors
AU2006210392A1 (en) * 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
US7887522B2 (en) 2005-03-18 2011-02-15 The Procter And Gamble Company Pull-on wearable article with informational image
US7806880B2 (en) * 2005-03-18 2010-10-05 The Procter & Gamble Company Pull-on wearable article with informational image
US20060264858A1 (en) * 2005-05-20 2006-11-23 Roe Donald C Multi-functional training garment
AU2006279612B2 (en) 2005-08-15 2013-03-21 Altimmune Inc. Immunization of avians by administration of non-replicating vectored vaccines
US7432413B2 (en) 2005-12-16 2008-10-07 The Procter And Gamble Company Disposable absorbent article having side panels with structurally, functionally and visually different regions
US8664467B2 (en) 2006-03-31 2014-03-04 The Procter & Gamble Company Absorbent articles with feedback signal upon urination
EP2035041B1 (de) * 2006-06-30 2020-01-08 Syntab Therapeutics GmbH Konjugate für die immanente immuntherapie bei krebs
US7896858B2 (en) * 2006-12-04 2011-03-01 The Procter & Gamble Company Absorbent articles comprising graphics
WO2009137577A2 (en) 2008-05-08 2009-11-12 Merial Limited Leishmania vaccine using sand fly salivary immunogen
US9400873B2 (en) 2011-12-21 2016-07-26 Deka Products Limited Partnership System, method, and apparatus for dispensing oral medications
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
RS58289B1 (sr) 2011-07-20 2019-03-29 Merial Ltd Rekombinantna vakcina protiv virusa mačje leukemije koja sadrži optimizovani gen omotača virusa mačje leukemije
CA2844927C (en) 2011-08-12 2017-10-31 Merial Limited Vacuum-assisted preservation of biological products, in particular of vaccines
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
US10563681B2 (en) 2011-12-21 2020-02-18 Deka Products Limited Partnership System, method, and apparatus for clamping
NZ700470A (en) 2012-03-20 2016-04-29 Merial Inc Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof
WO2013170433A1 (en) 2012-05-15 2013-11-21 The Procter & Gamble Company Absorbent article having characteristic waist end
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
WO2015175672A1 (en) 2014-05-14 2015-11-19 Merial, Inc. Methods for freeze-drying and rehydrating biologics
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
KR102726776B1 (ko) * 2021-07-09 2024-11-06 포항공과대학교 산학협력단 포밀 메티오닌 특이 항체 제조를 위한 신규한 항원 펩타이드

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US5861158A (en) * 1993-11-17 1999-01-19 The United States Of America As Represented By The Deptartment Of Health And Human Services Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor

Also Published As

Publication number Publication date
DE69935866D1 (de) 2007-05-31
HK1110769A1 (en) 2008-07-25
CA2342609A1 (en) 2000-06-22
NZ510544A (en) 2003-04-29
US6017537A (en) 2000-01-25
PT1140166E (pt) 2007-06-27
WO2000035482A3 (en) 2000-10-26
EP1800692A1 (de) 2007-06-27
AU773697B2 (en) 2004-06-03
ES2358540T3 (es) 2011-05-11
CY1106635T1 (el) 2012-01-25
PT1800692E (pt) 2011-03-31
AU2845100A (en) 2000-07-03
EP1140166A2 (de) 2001-10-10
EP1800692B1 (de) 2011-01-26
CY1111372T1 (el) 2015-08-05
DK1800692T3 (da) 2011-03-28
EP1140166B1 (de) 2007-04-18
DE69935866T2 (de) 2008-01-10
JP2002532436A (ja) 2002-10-02
SI1140166T1 (sl) 2007-08-31
DK1140166T3 (da) 2007-07-02
WO2000035482A2 (en) 2000-06-22
DE69943170D1 (de) 2011-03-10
ES2284285T3 (es) 2007-11-01
CA2718376A1 (en) 2000-06-22
SI1800692T1 (sl) 2011-05-31
ATE359817T1 (de) 2007-05-15
CA2342609C (en) 2010-11-16

Similar Documents

Publication Publication Date Title
DE69943170D1 (de) Immunologische Zusammensetzung und Impfstoffe, die einen auf N-Formyl-Methionyl Peptide bestehenden Adjuvans enthalten
DK0608261T3 (da) Sammensætninger med immunreaktivt hepatitis C virus polypeptid
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
BG98523A (en) Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b
DE69333397D1 (de) Retro-, inverso-, und retro-inverso synthetische peptidanaloge
KR890701125A (ko) 무병원성 미생물 및 이의 용도
DE69327587D1 (de) Konjugate von schwach immunogenen antigenen und synthetischen peptidträgern und impfstoffe diese enthaltend
ATE320493T1 (de) Modifizierung des hepatitis b kernantigens
ES8500997A1 (es) Un metodo para producir un peptido.
NO964862L (no) Papillomavirusvaksiner
WO2003088995A3 (en) Mucin fusion polypeptide vaccines, compositions and methods of use thereof
ATE141328T1 (de) Rekombinante vakzine gegen coccidiose
ATE103294T1 (de) Peptidfragmente von hiv.
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
ATE72400T1 (de) Kreuzreaktive und schuetzende epitope von circumsporozoit-proteinen.
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
UA42741C2 (uk) Пептид маститної вакцини (варіанти), пептид складного антигенного представлення (варіанти), фармацевтична композиція (варіанти)
ATE312923T1 (de) Moraxella catarrhalis basb034 polypeptide und verwendungen davon
DE69130675D1 (de) Klonierung und expression eines rhoptry-assoziierten proteins aus p. falciparum
NZ501427A (en) Vaccine compositions comprising the Helicobacter pylori FlgE (flagella) polypeptide and a mucosal adjuvant
WO1999022763A3 (en) Encapsulated immunomodulators useful as vaccine adjuvants
NZ532271A (en) Peptide mimics of conserved gonococcal epitopes and methods and compositions using them
IL108419A (en) Proteinaceous extract derived from eimeria maxima gametocytes and vaccines against eimeria maxima containing the same
NZ335929A (en) Use of a recombinant polypeptide having a glycosyl-phosphatidylinositol anchor for inducing an immune response

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1800692

Country of ref document: EP